- Trade Name: Synagis (Medimmune)
- Indications: Prophylaxis of serious lower respiratory tract disease caused by respiratory syncytial virus in pediatric patients
- Class: Immunomodulator, Monoclonal antibody
- Half-life: 18 days
- Clinically important, potentially hazardous interactions with:
None known
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
